COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
European Journal of Neurology2020Vol. 28(10), pp. 3384–3395
Citations Over TimeTop 1% of 2020 papers
Ana Zabalza, Simón Cárdenas‐Robledo, Paula Tagliani, Georgina Arrambide, Susana Otero‐Romero, Pere Carbonell‐Mirabent, Marta Rodríguez‐Barranco, Breogán Rodrı́guez‐Acevedo, Juan Luis Restrepo‐Vera, M. Resina-Salles, Luciana Midaglia, Ángela Vidal‐Jordana, Jordi Río, Ingrid Galán, Joaquín Castilló, Álvaro Cobo‐Calvo, Manuel Comabella, Carlos Nos, Jaume Sastre‐Garriga, Mar Tintoré, Xavier Montalbán
Abstract
Multiple sclerosis patients present similar incidence, risk factors and outcomes for COVID-19 as the general population. Patients treated with an anti-CD20 therapy for a longer period of time might be at a higher risk of COVID-19 and less than 20% generate an antibody response. Only age was related to severity.
Related Papers
- → Cardiovascular surgery risk prediction from the patient’s perspective(2011)6 cited
- → Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy(1980)3 cited
- INCIDENCE AND RISK FACTORS OF NEW ONSET DIABETES MELLI-TUS AMONG TRANSPLANTED RENAL ALLOGRAFT RECIPIENTS(2010)
- → Factors related to the incidence of symptoms and signs of temporomandibular joint disorders in persons staying at institutions for the elderly.(2001)
- Abnormal MRI in acute optic neuritis and follow-up of patients with regard to multiple sclerosis(1997)